NetraMark Holdings (XCNQ:AIAI) Common Stock : C$29.31 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is NetraMark Holdings Common Stock?

NetraMark Holdings's quarterly common stock increased from Sep. 2023 (C$28.82 Mil) to Dec. 2023 (C$29.07 Mil) and increased from Dec. 2023 (C$29.07 Mil) to Mar. 2024 (C$29.31 Mil).

NetraMark Holdings's annual common stock increased from Sep. 2021 (C$11.75 Mil) to Sep. 2022 (C$24.25 Mil) and increased from Sep. 2022 (C$24.25 Mil) to Sep. 2023 (C$28.82 Mil).

NetraMark Holdings Common Stock Historical Data

The historical data trend for NetraMark Holdings's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NetraMark Holdings Common Stock Chart

NetraMark Holdings Annual Data

Trend

Sep20

Sep21

Sep22

Sep23

Common Stock

1.95

11.75

24.25

28.82

NetraMark Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Common Stock	Get a 7-Day Free Trial										25.08	26.11	28.82	29.07	29.31

NetraMark Holdings Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

NetraMark Holdings (XCNQ:AIAI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » NetraMark Holdings Inc (XCNQ:AIAI) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

AINMF:USA

Address

1655 Dupont Street, Suite 101, Toronto, ON, CAN, M6P 3T1

Website

https://www.nurosene.com

NetraMark Holdings Inc is focused on the application of a totally unique Artificial Intelligence (AI) / Machine Learning (ML) solution targeted at the pharmaceutical industry in order to de-risk clinical trials. NetraMark has a proprietary technology that is capable of cutting through the combinatorial complexity that comes with dealing with heterogeneous patient populations to extract precisely defined personas of patients with respect to placebo and drug response, in addition to tolerability and adverse events. By using the client's own contemporaneous data, and having the capacity to learn from small data, the NetraAI tech extracts these personas to equip pharmaceutical companies with strategies to optimize their next trials for success.

Executives

Andrew Parks

Director

NetraMark Holdings (XCNQ:AIAI) Headlines

No Headlines